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There has been great interest in the prospects of using single-nucleotide polymorphisms (SNPs) in the search for
complex disease genes, and several initiatives devoted to the identification and mapping of SNPs throughout the
human genome are currently underway. However, actual data investigating the use of SNPs for identification of
complex disease genes are scarce. To begin to look at issues surrounding the use of SNPs in complex disease studies,
we have initiated a collaborative SNP mapping study around APOE, the well-established susceptibility gene for
late-onset Alzheimer disease (AD). Sixty SNPs in a 1.5-Mb region surrounding APOE were genotyped in samples
of unrelated cases of AD, in controls, and in families with AD. Standard tests were conducted to look for association
of SNP alleles with AD, in cases and controls. We also used family-based association analyses, including recently
developed methods to look for haplotype association. Evidence of association ( ) was identified for 7 of 13P  .05
SNPs, including the APOE-4 polymorphism, spanning 40 kb on either side of APOE. As expected, very strong
evidence for association with AD was seen for the APOE-4 polymorphism, as well as for two other SNPs that lie
!16 kb from APOE. Haplotype analysis using family data increased significance over that seen in single-locus tests
for some of the markers, and, for these data, improved localization of the gene. Our results demonstrate that
associations can be detected at SNPs near a complex disease gene. We found that a high density of markers will
be necessary in order to have a good chance of including SNPs with detectable levels of allelic association with the
disease mutation, and statistical analysis based on haplotypes can provide additional information with respect to
tests of significance and fine localization of complex disease genes.
Introduction
As human genetics moves toward identification of genes
contributing to the susceptibility to common disorders
and pharmacogenetic interactions, the mapping of traits
has incorporated more techniques relying on genetic as-
sociations. Methods based on marker/disease associa-
tions can provide powerful tools for identification of
disease loci. For localization of genes, association-based
methods can be more powerful than linkage analysis,
particularly when the contribution of these genes to the
disease is small, as would be expected for complex dis-
eases (Risch and Merikangas 1996). However, in order
for association analysis to be useful, a dense map of
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markers will be required, since associations can generally
only be found over small distances.
Recently, there has been great emphasis focused
on identification of single-nucleotide polymorphisms
(SNPs) in the human genome. It is anticipated that,
during the next 3 years, 100,000–200,000 SNPs will
be identified by the Human Genome Project (Collins et
al. 1998). Through a separate initiative, The SNP Con-
sortium has been formed, with the goal of generating
300,000 SNPs during the next 2 years (Marshall 1999).
SNPs have been postulated to be useful tools for iden-
tification of complex disease genes through association
studies and, as such, are the next wave of markers for
use in genetic analysis. It is estimated that SNPs occur,
on average, every 1,000 bp and have a low mutation
rate, both of which are characteristics that may have
particular advantages for association analysis.However,
as biallelic markers, SNPs are generally less informative
than are microsatellite markers, which may be a dis-
advantage for both association and linkage analyses.
Although great progress already has been made to-
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Figure 1 Physical map of SNPs on cosmid F19374 containing APOE
ward SNP development, several methodological ques-
tions remain to be addressed, in order to make optimal
use of this growing resource of SNP markers. What
density of SNPs should be used in analyses? Should
SNPs be chosen specifically in genes or distributed ran-
domly? Does knowledge of regional linkage disequilib-
rium help in the analysis? Is the frequency of the alleles
of practical importance? What statistical methodology
is most useful in the search for associations?What effect
will the large number of multiple statistical effects have
on the analysis? Can information from multiple SNPs
be combined to improve the ability to detect and fine-
map disease loci?
To begin to look at these questions, we have initiated
a collaborative SNP-mapping study around APOE
(MIM 107741), the well-established susceptibility gene
for late-onset Alzheimer disease (AD) (MIM 104300).
It is important to realize that this gene was identified
using both traditional linkage analysis (Pericak-Vance
et al. 1991) and association analysis (Corder et al. 1993;
Saunders et al. 1993; Strittmatter et al. 1993a). Studies
of APOE in primates and other mammals have sug-
gested that APOE-4, the allele associated with AD, is
the ancestral allele in humans (Hanlon and Rubinsztein
1995; Gerdes et al. 1996), and therefore it is expected
that linkage disequilibrium will extend only over small
distances. Thus, the APOE-4 allele should provide a
rigorous challenge for gene identification through as-
sociation analysis. Furthermore, there is a complex re-
lationship between the APOE-4 genotype and disease
status, with the APOE-4 allele being neither necessary
nor sufficient for AD but, instead, modulating the risk
for development of AD (Corder et al. 1993, 1994). This
should make the results of this experiment especially
useful in the definition of parameters and techniques for
the utilization of SNPs in the mapping of common com-
plex diseases. An initial analysis of 10 SNPs around
APOE has suggested that a limited region of association
surrounds the APOE gene (Vance et al. 1998; Martin
et al. 2000). Here we describe additional analysis of 60
SNPs surrounding APOE, conducted to further inves-
tigate the model.
Subjects and Methods
Subjects
The case-control sample was composed of 220 cases
with AD in which the age at onset was 159 years, mostly
isolated (sporadic) cases collected at the Bryan Alzhei-
mer’s Disease Research Center (Bryan ADRC) at the
Duke University Medical Center , and 220 controls in
the same age group, most of whom were spouses of
patients with AD. A small number of controls were
spouses of known non-AD dementia patients collected
at the Bryan ADRC. To improve homogeneity, all in-
dividuals included in this study were white. The family
sample was composed of 184 families from the National
Institute of Mental Health AD Genetics Initiative and
the Indiana University AD Cell Repository (Blacker et
al. 1997; Pericak-Vance et al. 1997). Of these 184 fam-
ilies, 92 contained phenotypically discordant sib pairs
(one affected and one unaffected sibling), 60 contained
at least two affected siblings and one unaffected sibling,
and 32 had no unaffected siblings but contained at least
one affected sib pair. This study focused on late-onset
AD; thus, we required that the age at onset in each
affected individual be 159 years. For the family data,
we required that the age at onset be 159 years for all
sampled affected family members, even if they were not
selected from our database for this study.
SNP Generation and Mapping
We have previously described the generation of these
SNPs (Lai et al. 1998) by using two different methods:
YAC truncation and random sequencing. Mapping of
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Figure 2 Plot of minus log of P value for case-control test for allelic association with AD, for SNPs immediately surrounding APOE
(!100 kb).
the majority of the markers used the TNG4 radiation-
hybrid panel. Additional mapping information came
from restriction-enzyme digestion and subsequent hy-
bridization of selected probes on cosmids containing
APOE, as well as from published maps (Freitas et al.
1998) and available cosmid sequences from GenBank.
Genotyping
Detection was performed by TaqMan assay in 96-
well plates after optimization for each primer set (Heid
et al. 1996). This technique uses two probes, each com-
plementary to one of the SNP alleles. Each probe con-
tains a different-colored tag, whose fluorescent activity
is prevented by the close presence of a “quencher” mol-
ecule, located on the other end of the probe. During
PCR, the probe hybridizes downstream from the PCR
primer, at the SNP site, creating a small double-strand
segment. The 5′-3′ exonucleolytic activity of Taq DNA
polymerase cleaves the probe as it replicates the tem-
plate, releasing the fragmented probe into the solution,
thus separating the quencher from the fluorescent tag.
This allows the tag to excite in the presence of a laser,
releasing the genotype-identifying color. DNA samples
were quantitated twice, in duplicate, by PicoGreen fluo-
rescent dye (Molecular Probes), and volumes were ad-
justed to ensure uniform concentration. A Hydra 96-
well multipipetter (Robbins) was used to distribute 20
ng of DNA to each well. Samples of DNA from the
Centre d’E´tude du Polymorphisme Humain, which were
sequenced for each SNP, were used as controls for each
genotype. The DNA was allowed to dry, and 25 ml of
master mix (8% glycerol, 1 # TaqMan buffer A, 5
mM MgCl2, 200 mM dATP, 200 mM dCTP, 200 mM
dGTP, 400 mM dUTP, 0.05 U of AmpliTaq Gold DNA
polymerase/ml, and 0.01 U of primer and probe/ml ) was
dispensed to each well, by a MultiProbe 204DT (Pack-
ard Instruments). The reaction was run on a GeneAmp
PCR System 9700 (50C for 2 min, 95C for 10 min,
and 95C for 15 s; and 62C for 1 min, for 35 cycles)
and was read on an ABI Prism 7200 sequence detector.
Since the subjects in this study had minimal or no
family structure, samples for six individuals were du-
plicated for each 96-well plate, to help detect potential
loading and reading errors. This is a slight modification
of the normal quality-control measures used by theDuke
Center for Human Genetics in the genotyping of com-
plex disorders (Rimmler et al. 1998). Technicians per-
forming and reading the polymorphisms were blinded
to the location of the duplicated samples. quality-control
samples were compared in the Duke Center for Human
Genetics Data Coordinating Center. Tests for deviation
from Hardy-Weinberg equilibrium (HWE) also were
conducted for all loci.
Statistical Analyses
Association analyses were conducted on the samples
of cases and controls and in the family sample. In the
case-control sample, allele and genotype frequencies
were compared between case and control groups, by
standard x2 tests for equality of proportions. To test for
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Figure 3 Plots of minus log of P value for TRANSMIT single-point and haplotype analysis of association at six SNPs in APOE region,
including (a) and excluding (b) APOE-4 (SNP528).
association in the family sample, we used the weighted
sibship disequilibrium test (WSDT) (Martin et al. 1999),
which provides a valid test for association in sibships of
arbitrary size. The WSDT is based on the difference be-
tween the number of times that a particular marker allele
occurs in affected individuals and the number of times
that the allele occurs in their unaffected siblings. x2 Ap-
proximations were used to calculate P values. Since 32
families had only affected siblings, thereby lacking the
unaffected sibling required for the sibship tests described
above, we also used a likelihood-based method from the
program TRANSMIT (Clayton 1999), which does not
require unaffected siblings. This method also was used
to look for excess transmission of SNP haplotypes to
affected individuals, providing an analysis of haplotype
association, in contrast to the single-locus tests. There
were nine extended pedigrees in our sample. For each
of these, a single nuclear family was sampled, without
respect to genotypes, for analysis in TRANSMIT. The
WSDT remains a valid test of linkage disequilibrium,
even in extended pedigrees.
Tests for allelic associations between pairs of markers
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Figure 4 Plots of location of marker pairs with significant ( ) allelic association in controls (a) and cases (b)P ! .01
were conducted in the case and control samples sepa-
rately, by the GDA (genetic data analysis) program
(GDA: Software for the Analysis of Discrete Genetic
Data). We used an exact test based on the multinomial
probability of the multilocus genotype, conditional on
the single-locus genotypes (Zaykin et al. 1995). Signif-
icance was assessed by Monte Carlo simulation, by per-
muting the single-locus genotypes among individuals in
the sample to simulate the null distribution. For each
pair of SNPs, 3,200 replicate samples were simulated,
to estimate the empirical P value. Since the single-locus
genotypes are preserved in the Monte Carlo method, the
test is not sensitive to deviations due to Hardy-Weinberg
disequilibrium.
Two-point and multipoint linkage analyses were con-
ducted by use of the package SIBLINK (Hauser and
Boehnke 1998). Allele frequencies for input were esti-
mated from the family data. Distances between markers
for multipoint analyses were approximated on the basis
of physical distance, with 1 Mb = 1 cM being assumed,
with a minimum map distance of 0.001 cM between
adjacent markers; although distance is known to be var-
iable across the genome, comparison of the chromosome
19 physical map from Lawrence Livermore National
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Figure 5 Two-point (dots) and multipoint (lines) LOD scores from linkage analyses
Laboratory (Murray et al. 1994) versus the integrated
genetic map (Ashworth et al. 1995) shows that the ap-
proximation 1Mb = 1cM may not be unrealistic for the
region surrounding APOE. Parametric two-point LOD
scores for dominant and recessive affecteds-only models
assuming a disease-allele frequency of .15 were calcu-
lated by FASTLINK (version 4.0) (Lathrop et al. 1984).
Results
Table 1 shows distances, calculated by radiation-hybrid
analysis, between the SNPs and APOE-4 (SNP528), es-
timates of allele frequencies in controls, and P values
both for tests of Hardy-Weinberg disequilibrium (in the
cases, in the controls, and in the combined sample), and
for case-control tests (based on genotypes and on alleles)
for association with AD. The SNPs analyzed span ∼1.5
Mb distal to APOE and ∼190 kb proximal. More SNPs
were identified on the distal side, as a result of the high
efficiency of the random sequencing approach that was
used to generate SNPs on that side. No attempt was
made to select markers with high allele frequencies, since
allele frequency was one of the parameters of interest in
this study. However, by using only seven controls to
screen for polymorphisms, we naturally were biased to-
ward detection of common polymorphisms. Neverthe-
less, several SNPs had quite low allele frequencies. In
fact, for SNP491, there was no variation observed in the
controls and only 10 copies of one of the alleles were
observed in the cases.
In table 1, we have indicated P values that are sig-
nificant at the .05 level and those that are significant at
the level of .0008, which is appropriate for an overall
significance level of .05 when a Bonferroni correction
is used to adjust for comparisons at the 60 SNPs. No-
tably, because of the exploratory nature of this work,
we have not attempted to correct for either multiple
comparisons in the different groups (i.e., cases, controls,
and combined sample) or for the different types of anal-
yses conducted. There is little evidence for deviation
from HWE at most of the markers. Only tests for
Hardy-Weinberg disequilibrium at SNP501 and a few
markers surrounding it are significant ( ) whenP  .0008
we correct for multiple comparisons. The minor allele
for SNP501 has a very low frequency (.017 in controls),
and therefore the expected genotype counts for the num-
ber of homozygotes for that allele are very small. This
brings into question the appropriateness of the x2 test
for Hardy-Weinberg disequilibrium for this marker. An
exact test of significance, rather than relying on the x2
distribution, resulted in for the test of Hardy-P = .0002
Weinberg disequilibrium in the cases. Although this
Table 1
Approximate Location of SNPs, Estimate of Allele Frequencies in Controls, and P Values for Tests of Hardy-Weinberg Disequilibrium and
for Association with AD in Cases and Controls
LOCUS a
APPROXIMATE
DISTANCE TO
APOE
ALLELE
FREQUENCY
IN CONTROLS
P FOR
HARDY-WEINBERG DISEQUILIBRIUM, IN CASE-CONTROL ASSOCIATION
Controls Cases Total Genotypic Allelic
SNP512 1,520 kb .15 .34 .99 .73 .0096 * .0033 *
SNP501 1,470 kb .017 .8 **205.6#10 **136.2#10 .1 .55
SNP459 1,405 kb .49 .073 .00012 ** .15 .00025 ** .41
SNP460 1,405 kb .0023 .97 .97 .96 1 1
SNP461 1,405 kb .091 .00047 ** .99 .025 * .048 .18
SNP489 1,335 kb .48 .59 .73 .84 .3 .15
SNP491 1,300 kb 0 No data .72 .8 .0012 * .0013 *
SNP517 1,240 kb .44 .074 .077 .013 * .45 .23
SNP524 1,230 kb .036 .6 .35 .3 .07 .078
SNP522 1,220 kb .081 .59 .83 .58 .29 .12
SNP525 1,195 kb .0092 .89 .78 .77 .23 .23
SNP511 1,060 kb .13 .82 .02 * .11 .024 * .063
SNP510 1,050 kb .13 .071 .46 .049 .24 .084
SNP509 1,030 kb .15 .014 * .55 .15 .14 .47
SNP506 995 kb .15 .014 * .5 .17 .13 .53
SNP507 995 kb .16 .042 * .36 .37 .13 .49
SNP502 945 kb .14 .018 * .22 .44 .058 .95
SNP505 935 kb .44 .82 .89 .79 .81 .52
SNP469 900 kb .12 .84 .22 .5 .42 .37
SNP470 900 kb .44 .52 .91 .59 .86 .69
SNP466 830 kb .36 .088 .02 * .0038 * .37 .15
SNP467 830 kb .47 .79 .71 .78 .034 * .01 *
SNP468 830 kb .34 .55 .69 .84 .14 .062
SNP473 630 kb .11 .008 * .66 .041 * .11 .12
SNP481 570 kb .19 .8 .03 * .1 .2 .21
SNP462 535 kb .48 .48 .91 .59 .34 .17
SNP463 515 kb .29 .0064 * .78 .042 * .077 .24
SNP458 475 kb .3 .98 .5 .65 .87 .84
SNP497 455 kb .37 .07 .67 .47 .004 * .0041 *
SNP479 425 kb .3 .43 .11 .56 .019 * .026 *
SNP521 240 kb .33 .22 .99 .37 .57 .52
SNP496 230 kb .46 .8 .67 .9 .69 .48
SNP514 210 kb .09 .3 .79 .54 .6 .51
SNP520 185 kb .36 .25 .73 .3 .69 .54
SNP527 160 kb .35 .31 .069 .05 .45 .3
SNP471 140 kb .47 .58 .32 .85 .059 .035 *
SNP472 140 kb .33 .63 .38 .37 .21 .089
SNP982 !100 kb .39 .44 .0084 * .018 * .28 .5
SNP987 !100 kb .04 .58 .58 .43 .99 .99
SNP457 40 kb .47 .52 .43 .96 .21 .15
SNP464 35 kb .22 .081 .98 .21 .16 .16
SNP465 35 kb .41 .2 .056 .039 * .014 * .0059 *
SNP874 21 kb .13 .34 .67 .32 .74 .5
SNP992 2.5 kb .36 .12 .042 * .023 * .0099 * .0052 *
SNP528 (APOE) 0 kb .14 .69 .023 * .76 **208.7#10 **205.1#10
SNP952 2.8 kb .33 .86 .15 .36 .026 * .014 *
SNP873 6.4 kb .36 .094 .052 .017 * .069 .037 *
SNP887 8 kb .03 .67 .66 .54 .86 .86
SNP888 8.5 kb .46 .95 .36 .99 **54.10#10 **68.10#10
SNP877 14.4 kb .02 .79 .91 .78 .21 .21
SNP988 16 kb .22 .56 .29 .91 **94.30#10 **106.80#10
SNP533 40 kb .23 .13 .72 .39 .13 .13
SNP490 60 kb .44 .66 .23 .56 .4 .48
SNP492 80 kb .29 .079 .31 .053 .65 .51
SNP886 !100 kb .3 .53 .057 .074 .53 .54
SNP875 !100 kb .32 .48 .2 .17 .74 .55
SNP1006 !100 kb .3 .52 .68 .98 .12 .052
SNP494 100 kb .0023 .97 .89 .9 .16 .16
SNP535 190 kb .13 .14 .3 .76 .22 .94
SNP474 12 Mb .44 .34 .41 .22 .73 .45
a Order is distal to proximal.
* .P  .05
** .P  .0008
390 Am. J. Hum. Genet. 67:383–394, 2000
Table 2
P Values for Family-Based Tests of Association,
at 17 SNPs
P FOR
LOCUS WSDT TRANSMIT
SNP512 .1228 .8414
SNP459 .8617 .5421
SNP491 .5637 .5342
SNP497 .9984 .8583
SNP479 .0086 .0922
SNP471 .8255 .8687
SNP457 .5765 .6075
SNP465 .1520 .1103
SNP992 .0081 .0009
SNP528 (APOE) 68.02# 10 114.72# 10
SNP952 .0278 .00065
SNP873 .4709 .0351
SNP888 .1723 .0085
SNP988 .0031 51.41# 10
SNP886 .2364 .2124
SNP875 .3158 .2614
SNP1006 .9946 .8872
value is not as extreme as the that was20P = 5.6# 10
observed with the x2 test, it still meets our criteria for
significance after we correct for multiple tests.
Sixteen SNPs, including the APOE-4 polymorphism,
showed evidence for association ( ), with theP  .05
case-control test for either genotype- or allele-frequency
comparisons. A cluster of seven of these SNPs lies !40
kb from APOE. Four of the SNPs meet the criteria for
significant association with ADwhen we adjust for mul-
tiple tests: SNP459, SNP888, SNP988, and APOE-4 it-
self (SNP528), with the strongest associations being
found at SNP888, SNP988, and APOE-4. Markers
SNP888 and SNP988 are both found on the sequence
of cosmid F19374, along with APOE-4 and APOC1 (fig.
1). Previously, we had confirmed the reported associa-
tion of APOC1 with AD (Martin et al. 2000). The as-
sociation at the more distant marker, SNP459, still
meets our criteria for significance, yet the P value is
orders of magnitude larger—and, hence, much less sig-
nificant, than the P values for SNP888 and SNP988.
Thus, it is unlikely that this would have led us our
attention away from the region immediately surround-
ing APOE. Figure 2 shows a graphic representation of
the results for the case-control test for allelic association
with AD (table 1), for the SNPs closest to APOE. In
figure 2 are shown exon and intron locations of SNPs
in two genes. SNP988 and SNP888 lie in TOM40,
which codes for the mitochondrial outer-membrane
protein (LocusLink accession number 10452) (Ahting
et al. 1999). In the gene for this protein, neither exons
nor introns showed a greater trend toward association
with AD. SNP952, in the first exon (5′UTR) of APOE,
showed evidence for association comparable to that
seen at SNP992, which lies in an intron of APOE.
Family-based tests for association were conducted on
a subset of 17 of the 60 SNPs. Criteria includedmarkers
immediately surrounding APOE, as well as those mark-
ers that showed significant results in the case-control
analysis. The P values for the two family-based tests are
shown in table 2. The results from the family-based
tests of association are consistent with the case-control
results, in showing that significant associations are con-
centrated at SNPs near APOE; however, the family-
based tests are generally less significant than the case-
control tests. This is likely a result of lower power for
the family-based tests, because of the smaller size of the
family sample relative to the case-control sample.
Figure 3 shows the results from the haplotype anal-
yses for TRANSMIT. Six SNPs, those falling on the
cosmid and genotyped in the family data, were consid-
ered in these analyses. Bars indicating significance (mi-
nus log of the P value) of two-locus and three-locus
haplotype analyses are shown in figure 3. Two-locus
and three-locus analyses examined haplotypes for each
successive set of adjacent SNPs. The analysis was con-
ducted including SNP528 (APOE-4) (fig. 3a) and ex-
cluding SNP528 (fig. 3b) from the analysis. For com-
parison, single-locus test results also are shown. Not
surprisingly, when we included SNP528 in the anal-
ysis, the strongest single-locus result was for SNP528
(APOE-4) ( ), and the strongest re-11P = 4.7# 10
sults for the haplotype analyses were for haplotypes
containing SNP528 (two-locus haplotype SNP952-
SNP528, ; three-locus haplotype11P = 3.7# 10
SNP873-SNP952- SNP528, ). When12P = 2.6# 10
SNP528 (APOE-4) is excluded from the analysis, the
most significant results are for the haplotypes containing
those markers immediately proximal to SNP528 (two-
locus haplotype SNP873-SNP952, ;6P = 2.0# 10
three-locus haplotype SNP888-SNP873-SNP952, P =
). Interestingly, the results of haplotype anal-72.4# 10
yses with SNP888, SNP873, and SNP952 are notably
more significant than those of the single-locus tests for
association at these markers. The most significant sin-
gle-locus result, if SNP528 is excluded, is for a more
distant marker, SNP988 ( ). Thus, when5P = 1.4# 10
SNP528 is excluded, the haplotype analysis both in-
creases significance and helps to better localize the dis-
ease gene, compared with the single-locus analysis. It is
interesting, however, that the haplotypes with the most-
significant results do not contain the APOE suscepti-
bility locus but do point to a region slightly proximal
to APOE.
Figure 4 shows the pairwise comparisons for allelic
associations between SNPs that . Analyses wereP ! .01
conducted among the controls (fig. 4a) and among the
cases (fig. 4b). The results follow the expected distri-
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bution, along a diagonal, that would be expected for
allelic associations occurring between those markers
close to one another; however, it can be seen that the
distance over which significant association can be de-
tected differs greatly within the region. Significant as-
sociations were identified between SNPs as distant as
1,200 kb in the controls and 1,400 kb in the cases.
Generally, associations were found spanning a larger
distance in the case group than in the control group.
Strong associations were identified between SNP528
(APOE-4) and both SNP988 and SNP888, in both case
and control samples. This explains why, in our case-
control analysis, we detected such strong evidence of
association between these SNPs and AD.
Figure 5 shows the results from our linkage analyses.
Two-point maximum LOD scores are shown, and two
multipoint curves, one including and one excluding the
APOE-4 SNP (SNP528), are shown in the plot. Clearly,
the linkage analyses give good evidence for linkage to
a disease gene in the region. The two-point LOD score
of 5.5 at SNP528 gives very strong evidence for linkage,
and the multipoint curve including SNP528 maximizes,
with a LOD score of almost 2, at the position corre-
sponding to the location of SNP528. Even when the
disease polymorphism, SNP528, is excluded, there is
evidence for linkage, on the basis of the multipoint anal-
yses (LOD score 11), and the curve maximizes at the
correct position. It is of note that the interval examined
was not broad enough to allow us to bound the linkage
on the proximal side of APOE. Results from parametric
linkage analyses (data not shown) were qualitatively
similar to those from nonparametric linkage analyses.
Both dominant and recessive models give the strongest
two-point LOD scores for SNP528.
Discussion
This study demonstrates that associations can be de-
tected at SNPs near a complex disease gene. However,
it is clear that, in order to detect association, the “right”
SNPs must be chosen. Of 13 SNPs genotyped at !40 kb
from the APOE-4 polymorphism, 7 (including APOE-
4) showed evidence of association with AD ( ).P  .05
The APOE-4 SNP and two other SNPs lying !16 kb
from APOE-4 showed strong evidence of association.
Since the strongest associations were detected !16 kb
from the disease polymorphism, does this suggest that
a map density of 32 kb would be adequate for detection
of association with AD? Several of the SNPs closest to
the APOE-4 SNP showed only marginal evidence or no
evidence of association with AD. Thus, even assuring
that one SNP !16 kb of the disease locus was chosen
would not guarantee that an association could be iden-
tified. Using a greater density of markers would be de-
sirable, since it increases the chance of including any
markers with significant association with the disease. For
this reason, the efforts underway to identify hundreds
of thousands of SNPs spanning the genome appear to
be well justified. Of course, it should be noted that this
is a very limited example, and the required density of
markers will surely vary depending on the disease under
study and the region of the genome being analyzed.
It has been suggested that, for identification of com-
plex disease loci, SNPs in coding regions may be more
useful than those in noncoding regions. However, we
find that, unless a functional SNP directly influencing
disease susceptibility (e.g., APOE-4) is included in the
battery of markers tested, there is no clear advantage
to SNPs in exons rather than in introns. Thus, this anal-
ysis strongly suggests that success in finding an asso-
ciation rests on having a high density of SNPs. As can
be seen in figure 4, areas of association will differ along
the chromosome, and this may be useful in predicting
the necessary density of SNPs for studies.
The reduction in the number of markers demonstrat-
ing significance after correction for multiple compari-
sons is an important factor to consider. Although the
results of the tests for association at SNP988 and
SNP888 are clearly significant in the case-control anal-
yses, it is easy to see that, if one is performing analysis
of a larger number of SNPs, the noise level is a signif-
icant problem. In fact, it is likely that, in a genomic
screen using as few as 10,000 SNPs, the test for asso-
ciation at SNP888 would not be significant if a standard
Bonferroni correction for multiple comparisons were
applied. It is important, however, to consider the tests
for association at the multiple markers considered
jointly. Several SNPs immediately surrounding APOE
show marginal significance, with . Perhaps see-P  .05
ing a region of markers with P values nearing signifi-
cance for association is an important indicator of the
presence of a disease gene and, as has been suggested
for linkage analysis, will help distinguish true positives
from false positives (Terwilliger et al. 1997).
Haplotype analysis to investigate associations be-
tween disease loci and multiple markers could be a val-
uable tool for the use of SNPs in complex disease. In
this study, in the families with AD, the haplotype anal-
yses conducted for SNPs around APOE did increase
significance and improve localization of the disease
gene. This is evidenced by the fact that analyses of two-
and three-locus haplotypes yielded results that were
more significant than those of the single-locus tests. Fur-
thermore, localization, when APOE-4 is not included in
the analysis, is improved by use of haplotypes, com-
pared with the use of single loci. These results suggest
that association analysis based on haplotypes may in-
deed be a powerful approach for mapping of complex
disease genes by use of SNPs.
The results for the family-based tests of association
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were generally less significant than the results for the
case-control test. This was not unexpected, since there
are a larger number of independent observations in the
case-control sample. In general, larger samples will need
to be obtained for family-based tests of association
(Martin et al. 1997). However, there are advantages to
a family-based design, such as robustness in stratified
populations, utility for both linkage and association
analyses, and the ability to conduct haplotype analyses,
which may outweigh the additional cost of the collec-
tion of larger samples.
It is difficult to say much about the effect of SNP
allele frequencies on association analysis; however, it
does appear that it may be preferable to use SNPs with
moderate allele frequencies, rather than SNPs with very
low allele frequencies. For example, in the case-con-
trol analysis, SNP988 shows highly significant associ-
ation with AD, yet neither SNP877 nor SNP887, both
of which are closer to APOE-4, shows evidence of as-
sociation with the disease. This could be due to their
low allelic frequencies, both of which are estimated to
be !.05 in controls (table 1). In fact, in the case-control
test, of the eight genotyped SNPs !20 kb from APOE-
4, only SNP877 and SNP887 have nonsignificant re-
sults, whereas the other six SNPs, all with allele fre-
quencies 1.14 in controls, show evidence of association
( ). Allele frequencies also influence the power ofP  .05
the family-based tests for association. Sibships in which
all siblings have the same marker genotype are not in-
formative. Thus, there will be fewer informative families
for markers with lower heterozygosity; for example, for
SNP491, only four informative families were observed,
and it is not surprising that the results of family-based
tests for association at this marker were not significant.
These data suggest that markers with very low allele
frequencies may not be particularly useful for associa-
tion analysis. However, this is not to suggest that only
SNPs with allele frequencies of ∼.5 should be chosen.
SNP528 and SNP988 have estimated allele frequen-
cies of .14 and .22, respectively, in the controls; how-
ever, the case-control and family-based tests for asso-
ciation at these SNPs are more significant than the tests
for all of the other SNPs, many of which are more
polymorphic.
One very interesting finding is that SNP952 and
SNP992, two SNPs in the APOE gene itself, are not
highly associated with AD. SNP952 is in the 5′UTR,
and SNP992 is intronic, suggesting that it is unlikely
that any selective pressures would maintain one allele
rather than another; although low allele frequency
would appear to be an obvious explanation of this find-
ing, the minor allele frequencies for these two SNPswere
.36 and .33, respectively (table 1). Thus, low allele fre-
quency does not appear to be a factor in this finding.
This example does suggest, however, that ruling out a
candidate gene as contributing to a disease state, par-
ticularly when SNPs in noncoding regions are used, may
be very difficult.
SNP988 (coding) and SNP888 (noncoding), two
SNPs showing strong evidence of association with AD,
lie in the TOM40 gene. The protein for which this gene
codes constitutes the primary component of the pro-
tein-conducting channel of the outer mitochondrial
membrane. However, the SNP988 base change is silent,
producing no change in the amino acid coded. Thus, as
in the case of APOC1, it is likely that the association
with AD is the result of linkage disequilibrium with the
APOE-4 allele. This illustrates the difficulty that can be
present in association studies when positive associations
with multiple biologically relevant genes are found.
All of the analyses conducted in this study give strong
evidence for existence of an AD gene in the region. The
results of association analyses would have allowed us
to narrow the region of interest to a relatively small
region containing the APOE gene. However, it is im-
portant to keep in mind that, even with the region nar-
rowed, there is still the challenge of identifying the ac-
tual gene involved. Findings of association with APOE
and AD have been widely replicated, and several lines
of evidence support a functional role of the APOE gene
in AD (Schmechel et al. 1993; Strittmatter et al. 1993a,
1993b). It was the convergence of positional and bio-
logical evidence, followed by the demonstration of as-
sociation with the functional polymorphism itself, that
ultimately led to the identification of the role of APOE
in AD. Therefore, a multidisciplinary approach for iden-
tification of genes influencing complex disease will most
useful.
Our analysis of SNPs in this region has clearly dem-
onstrated that it is possible to detect association at
markers near a disease polymorphism, even for a com-
plex disease in outbred populations. This study dem-
onstrates the need for a high density of SNP markers
and has found a benefit in the use of markers jointly in
haplotype analyses. We are continuing this investigation
by using this model, investigating the effects of haplo-
types and linkage disequilibrium in the region for AD,
in specialized populations.
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